[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201992651A1 - HUMAN ANTIBODIES K Bet v 1 AND WAYS OF THEIR APPLICATION - Google Patents

HUMAN ANTIBODIES K Bet v 1 AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201992651A1
EA201992651A1 EA201992651A EA201992651A EA201992651A1 EA 201992651 A1 EA201992651 A1 EA 201992651A1 EA 201992651 A EA201992651 A EA 201992651A EA 201992651 A EA201992651 A EA 201992651A EA 201992651 A1 EA201992651 A1 EA 201992651A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
bet
basophils
ways
bind
Prior art date
Application number
EA201992651A
Other languages
Russian (ru)
Inventor
Джейми М. Оренго
Эндрю Дж. МЕРФИ
Ашок Т. Бадите
Вишал Камат
Яшу Лю
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2018/035366 external-priority patent/WO2018222854A1/en
Publication of EA201992651A1 publication Critical patent/EA201992651A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем документе предусмотрены антитела, которые связываются с аллергенами Fagales, родственными Fagales аллергенами, пыльцой березы или Bet v 1, композиции, содержащие антитела, нуклеиновые кислоты, кодирующие антитела, и способы применения антител. Согласно определенным вариантам осуществления антитела представляют собой полностью человеческие моноклональные антитела, которые связываются с Bet v 1. Антитела являются применимыми для связывания Bet v 1 in vivo, таким образом предотвращая связывание аллергена с предварительно образованным IgE на поверхности тучных клеток или базофилов. Тем самым антитела действуют для предотвращения высвобождения гистамина и других медиаторов воспаления из тучных клеток и/или базофилов, тем самым уменьшая интенсивность неблагоприятного ответа на аллергены Fagales у сенсибилизированных пациентов.Antibodies are provided herein that bind to Fagales allergens, related Fagales allergens, birch pollen or Bet v 1, compositions comprising antibodies, nucleic acids encoding antibodies, and methods for using antibodies. In certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. Antibodies are useful for binding Bet v 1 in vivo, thereby preventing allergen from binding to preformed IgE on the surface of mast cells or basophils. Thus, antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and / or basophils, thereby reducing the intensity of the adverse response to Fagales allergens in sensitized patients.

EA201992651A 2018-04-24 2018-05-31 HUMAN ANTIBODIES K Bet v 1 AND WAYS OF THEIR APPLICATION EA201992651A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662165P 2018-04-24 2018-04-24
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201992651A1 true EA201992651A1 (en) 2020-04-07

Family

ID=70483863

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992651A EA201992651A1 (en) 2018-04-24 2018-05-31 HUMAN ANTIBODIES K Bet v 1 AND WAYS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201992651A1 (en)

Similar Documents

Publication Publication Date Title
CY1124819T1 (en) HUMAN ANTI-FEL D1 ANTIBODIES AND METHODS OF USING THEREOF
MX2023000390A (en) Human antibodies to bet v 1 and methods of use thereof.
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
NO20083715L (en) Antibodies against human IL-22 and uses thereof
EA200870129A1 (en) HUMAN ANTIBODIES AGAINST IL-23, COMPOSITIONS, METHODS AND APPLICATIONS
EP2447280A3 (en) VEGF analogs and methods of use
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
EA201290589A1 (en) CD127-BINDING PROTEINS
NO20083697L (en) Methods for using antibodies against human IL-22
WO2006125202A3 (en) Anti- mcp-1 antibodies, compositions, methods and uses
EA200901436A1 (en) Antigen-binding proteins that bind PAR-2
EP4339615A3 (en) Anti-pd-1 antibodies
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
MA32770B1 (en) Igf-1 polypeptide antibody
MX2020008403A (en) Cyclin a1 specific t cell receptors and uses thereof.
WO2016028523A3 (en) Antigen binding proteins that bind cxcr3
EP4272822A3 (en) Adamts binding immunoglobulins
EA201591898A1 (en) ANTIBODIES DIRECTED TO M-CSF
EA201992651A1 (en) HUMAN ANTIBODIES K Bet v 1 AND WAYS OF THEIR APPLICATION
WO2015077434A3 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
TH97938B (en) Human anti-IL-22 antibodies and methods of use for it
TH97938A (en) Human anti-IL-22 antibodies and methods of use for it
EA202092835A1 (en) ANTIBODIES BINDING TO ILT4
TH153721A (en) Antibody, Monochloral, Anti-Tissue Pathway Factor Inhibitors (TFPI)
TH136515A (en) High affinity antibodies against human angio-poitin-2-